Northern Trust Corp Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Northern Trust Corp lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 792,750 shares of the company’s stock after buying an additional 55,144 shares during the period. Northern Trust Corp owned approximately 0.93% of Syndax Pharmaceuticals worth $10,480,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of SNDX. R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at $26,000. Virtus ETF Advisers LLC boosted its position in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after buying an additional 827 shares during the last quarter. Cape Investment Advisory Inc. boosted its position in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV boosted its position in shares of Syndax Pharmaceuticals by 104.8% during the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after buying an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at $152,000.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Guggenheim reissued a “buy” rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Citigroup lowered their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a report on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. increased their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.91.

Syndax Pharmaceuticals Stock Up 1.1%

NASDAQ SNDX opened at $9.05 on Friday. The stock’s 50-day moving average price is $12.10 and its 200-day moving average price is $14.07. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.58 and a 52 week high of $25.07. The company has a market capitalization of $778.73 million, a P/E ratio of -2.49 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. The firm’s revenue for the quarter was up 1900.0% compared to the same quarter last year. During the same period last year, the business posted ($0.85) EPS. Research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).